NKLAM: An RBR E3 Ubiquitin Ligase Essential for Regulation of Innate Immunity

NKLAM:一种 RBR E3 泛素连接酶,对于调节先天免疫至关重要

基本信息

  • 批准号:
    9898218
  • 负责人:
  • 金额:
    --
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2012
  • 资助国家:
    美国
  • 起止时间:
    2012-04-01 至 2021-09-30
  • 项目状态:
    已结题

项目摘要

The innate immune system serves is the first response to diseased cells and infectious agents. Natural Killer (NK) cells and macrophages are primary components of this system. Although their functions differ, they both require the expression of NKLAM (Natural Killer Lytic-Associated Molecule) for optimal function. Accordingly, elucidating the role of NKLAM in innate immunity has important biological and clinical significance. NKLAM is up-regulated in NK cells upon exposure to tumor cells or cytokines that activate cytolytic function. NKLAM is up-regulated in macrophages upon exposure to bacteria or pro-inflammatory cytokines. We generated NKLAM-deficient (KO) mice; they have less NK activity than WT (wild type) mice. They exhibit greater tumor growth, tumor dissemination and metastasis than WT mice. NKLAM KO mice also have defects in macrophage anti-bacterial function in vivo and in vitro. NKLAM is a member of a small, highly conserved, unique group of RING-in between-RING (RBR) E3 ubiquitin ligases. RBR E3 ubiquitin ligases play a key role in cellular physiology and are involved in the pathogenesis of many diseases, including cancer, autoimmune diseases and neurological disorders. There is great interest in drug discovery to target them. We identified key potential substrates of NKLAM-mediated ubiquitination, including the transcription factors STAT1 and c-myc, Bcl-2 and UCKL-1 (uridine cytidine kinase like-1), a protein that promotes tumor growth. The central nature of these substrates in cell signaling, growth and survival suggests that drug modulation of NKLAM has significant potential for treating cancer and infectious diseases. We found that activated NK cells releases exosomes containing NKLAM. NKLAM+ exosomes promote tumor cell death in vitro. Preliminary data indicate that NKLAM+ exosomes enter target cells and deliver NKLAM. Important unanswered questions that will be addressed are the effect of NKLAM on critical substrates in effector cells and in target cells. The role of NKLAM in macrophages is undoubtedly different from its role in NK cells in that killing of bacteria occurs intracellularly. Our ongoing studies suggest that NKLAM modulates the signaling events that activate the macrophage anti-bacterial program. A key regulator of this pathway is STAT1. We will test the hypothesis that the E3 ubiquitin ligase activity of NKLAM plays a role in the anti-tumor and anti-microbial functions of NK cells and macrophages with the following three interconnected but independent aims: Aim 1: Elucidate the role of NKLAM in exosome-mediated killing of tumor cells. We will test the hypothesis that upon entry of NK-derived exosomes containing NKLAM into tumor cells, NKLAM interacts with critical substrates, resulting in cell death. We will test the ability of exosomes from NKLAM WT, NKLAM KO and NKLAM ligase defective NK cells to kill tumor cells in vivo using a mouse model of multiple myeloma, a disease increasing in frequency, especially in veterans. Aim 2: Determine how NKLAM affects the anti-bacterial function of macrophages in vitro and in vivo. We will infect NKLAM KO and WT mice with S. pneumoniae and S. aureus, pathogens that are leading causes of disease. In light of increasing antibiotic resistance, the importance of these in vivo studies is magnified. Aim 3: Identify the mechanism, sites and types of ubiquitination mediated by NKLAM. We will examine substrates important in tumor growth and anti-bacterial killing. This will provide a better understanding of the role of NKLAM in anti-tumor and anti-bacterial immunity and reveal key regulatory steps susceptible to therapeutic interventions for diseases that afflict our veteran population.
先天免疫系统是对病变细胞和感染因子的第一反应。自然 杀伤(NK)细胞和巨噬细胞是该系统的主要组成部分。虽然它们的功能不同,但 两者都需要表达NKLAM(自然杀伤细胞溶解相关分子)以实现最佳功能。 因此,阐明NKLAM在天然免疫中的作用具有重要的生物学和临床意义。 暴露于肿瘤细胞或激活溶细胞因子的细胞因子后,NKLAM在NK细胞中上调 功能在暴露于细菌或促炎细胞因子后,NKLAM在巨噬细胞中上调。我们 产生NKLAM缺陷型(KO)小鼠;它们具有比WT(野生型)小鼠更低的NK活性。他们表现出更大的 肿瘤生长、肿瘤扩散和转移的能力比WT小鼠强。NKLAM KO小鼠也具有以下缺陷: 巨噬细胞在体内和体外的抗菌功能。 NKLAM是一个小的,高度保守的,独特的环间环(RBR)E3组的成员 泛素连接酶。RBR E3泛素连接酶在细胞生理学中起着关键作用,并参与了细胞的生长。 许多疾病的发病机制,包括癌症、自身免疫性疾病和神经系统疾病。有 对药物研发的巨大兴趣。我们确定了NKLAM介导的 泛素化,包括转录因子STAT 1和c-myc,Bcl-2和UCKL-1(尿苷胞苷激酶 Like-1),一种促进肿瘤生长的蛋白质。这些底物在细胞信号传导、生长和代谢中的核心性质是: 存活表明NKLAM的药物调节对于治疗癌症和感染性疾病具有显著的潜力。 疾病 我们发现活化的NK细胞释放含有NKLAM的外泌体。NKLAM+外泌体促进 体外肿瘤细胞死亡。初步数据表明NKLAM+外泌体进入靶细胞并递送NKLAM。 将解决的重要未回答的问题是NKLAM对效应器中关键底物的影响。 细胞和靶细胞。 NKLAM在巨噬细胞中的作用无疑与其在NK细胞中的作用不同, 细菌发生在细胞内。我们正在进行的研究表明,NKLAM调节信号事件, 激活巨噬细胞的抗菌程序这条通路的一个关键调节因子是STAT 1。 我们将检验NKLAM的E3泛素连接酶活性在抗肿瘤中发挥作用的假设。 NK细胞和巨噬细胞的抗微生物功能与以下三个相互关联,但 独立目标: 目的1:阐明NKLAM在外泌体介导的肿瘤细胞杀伤中的作用。我们将测试 假设在含有NKLAM的NK衍生的外泌体进入肿瘤细胞后,NKLAM与 关键底物,导致细胞死亡。我们将测试来自NKLAM WT、NKLAM KO和NKLAM WT的外来体的能力。 NKLAM连接酶缺陷型NK细胞使用多发性骨髓瘤(一种疾病)小鼠模型在体内杀死肿瘤细胞 频率越来越高,尤其是退伍军人。 目的2:确定NKLAM如何在体外和体内影响巨噬细胞的抗菌功能。我们 将用S.肺炎链球菌和S.金黄色葡萄球菌,病原体是导致 疾病鉴于抗生素耐药性的增加,这些体内研究的重要性被放大。 目的3:确定NKLAM介导的泛素化的机制、位点和类型。我们将研究 在肿瘤生长和抗细菌杀伤中重要的底物。这将有助于更好地理解 NKLAM在抗肿瘤和抗细菌免疫中的作用,并揭示了对治疗敏感的关键调控步骤。 对折磨我们退伍军人的疾病进行干预。

项目成果

期刊论文数量(12)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Extracellular Vesicles From the Human Natural Killer Cell Line NK3.3 Have Broad and Potent Anti-Tumor Activity.
来自人类天然杀手细胞系NK3.3的细胞外囊泡具有广泛而有效的抗肿瘤活性。
E3 ubiquitin ligase NKLAM positively regulates macrophage inducible nitric oxide synthase expression.
  • DOI:
    10.1016/j.imbio.2014.08.016
  • 发表时间:
    2015-01
  • 期刊:
  • 影响因子:
    2.8
  • 作者:
    Lawrence, Donald W.;Gullickson, Gail;Kornbluth, Jacki
  • 通讯作者:
    Kornbluth, Jacki
E3 ubiquitin ligase NKLAM ubiquitinates STAT1 and positively regulates STAT1-mediated transcriptional activity.
  • DOI:
    10.1016/j.cellsig.2016.08.014
  • 发表时间:
    2016-12
  • 期刊:
  • 影响因子:
    4.8
  • 作者:
    Lawrence DW;Kornbluth J
  • 通讯作者:
    Kornbluth J
Natural Killer Lytic-Associated Molecule (NKLAM): An E3 Ubiquitin Ligase With an Integral Role in Innate Immunity.
  • DOI:
    10.3389/fphys.2020.573372
  • 发表时间:
    2020
  • 期刊:
  • 影响因子:
    4
  • 作者:
    Lawrence DW;Willard PA;Cochran AM;Matchett EC;Kornbluth J
  • 通讯作者:
    Kornbluth J
NK3.3-Derived Extracellular Vesicles Penetrate and Selectively Kill Treatment-Resistant Tumor Cells.
  • DOI:
    10.3390/cancers16010090
  • 发表时间:
    2023-12-23
  • 期刊:
  • 影响因子:
    5.2
  • 作者:
    Mccune, Allyson;Kornbluth, Jacki;Wong, David
  • 通讯作者:
    Wong, David
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

JACKI KORNBLUTH其他文献

JACKI KORNBLUTH的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('JACKI KORNBLUTH', 18)}}的其他基金

Molecular Characterization of Anti-Tumor Activity Mediated by Extracellular Vesicles Derived from Natural Killer Cells
自然杀伤细胞来源的细胞外囊泡介导的抗肿瘤活性的分子表征
  • 批准号:
    10587355
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Development of Natural Killer (NK) Cell Line-Derived Extracellular Vesicles as a New Treatment for Cancer
开发自然杀伤 (NK) 细胞系衍生的细胞外囊泡作为癌症的新治疗方法
  • 批准号:
    10383462
  • 财政年份:
    2022
  • 资助金额:
    --
  • 项目类别:
Analysis of NKLAM: A Novel Gene Associated With Cellular Cytotoxicity
NKLAM 分析:与细胞毒性相关的新基因
  • 批准号:
    8413781
  • 财政年份:
    2012
  • 资助金额:
    --
  • 项目类别:
Analysis of NKLAM: A Novel Gene Associated With Cellular Cytotoxicity
NKLAM 分析:与细胞毒性相关的新基因
  • 批准号:
    8696768
  • 财政年份:
    2012
  • 资助金额:
    --
  • 项目类别:
Analysis of NKLAM: A Novel Gene Associated With Cellular Cytotoxicity
NKLAM 分析:与细胞毒性相关的新基因
  • 批准号:
    8795661
  • 财政年份:
    2012
  • 资助金额:
    --
  • 项目类别:
Analysis of NKLAM: A Novel Gene Associated With Cellular Cytotoxicity
NKLAM 分析:与细胞毒性相关的新基因
  • 批准号:
    8243104
  • 财政年份:
    2012
  • 资助金额:
    --
  • 项目类别:
PLATELET-ACTIVATING FACTOR AND METASTASIS: CALCIUM-INDEPENDENT PHOSPHOLIPASE
血小板激活因子和转移:钙非依赖性磷脂酶
  • 批准号:
    8361461
  • 财政年份:
    2011
  • 资助金额:
    --
  • 项目类别:
Role of Natural Killer Lytic-Associated Molecule (NKLAM) in Natural Killer Functi
自然杀伤裂解相关分子 (NKLAM) 在自然杀伤功能中的作用
  • 批准号:
    8123617
  • 财政年份:
    2010
  • 资助金额:
    --
  • 项目类别:
NKLAM--A NOVEL GENE REQUIRED FOR NK FUNCTION
NKLAM--NK 功能所需的新型基因
  • 批准号:
    2103280
  • 财政年份:
    1993
  • 资助金额:
    --
  • 项目类别:
NKLAM--A NOVEL GENE REQUIRED FOR NK FUNCTION
NKLAM--NK 功能所需的新型基因
  • 批准号:
    2103282
  • 财政年份:
    1993
  • 资助金额:
    --
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了